The lack of standardized methods for new modalities means open discussions with advanced therapy clients are critical, says Charles River amid spiraling testing demand. Despite a slow start for the year, biologics testing is on the up for Charles River Laboratories. The life sciences services firm this month announced plans to set up shop at Wheeler Bio’s plant in Oklahoma, and at the recent BIO event in Boston spoke about a barrage of demand from advanced therapy makers. Referencing viral…
This webcast features: Florian Knoll, Scientist, Bibitec GmbH. Over the last decades, innovations have led to rapid development and growth in biopharmaceutical production, which has gone hand in hand with the urgent need for new medicines and treatments for today’s increasingly fast-growing society. In particular, upstream processing has benefited from new technologies in recent years, enabling high titers of therapeutic antibodies and antibody related products in the order of several kilograms. Therefore, downstream processing must now catch up to ensure…
Dyadic has signed a Memorandum of Understanding (Mou) with Essential Drugs Company Limited (EDCL) in Bangladesh to develop and improve its biomanufacturing infrastructure.  The EDCL is the state-owned pharmaceutical firm under the Ministry of Health and Family Welfare of Bangladesh, which aims to enable research, pre-clinical development, cGMP manufacturing, clinical trials, regulatory requirements, and various other areas of interest in the country.  According to Dyadic International, the partnership with the government of Bangladesh “demonstrates the company’s continued ability to leverage…
Market dynamics have reduced the early-stage pipeline but increasing demand for more work intensive later-phase projects is driving revenues for Avid Bioservices. For the full year ending April 30 2023, Avid Bioservices clocked in sales of $149.3 million, a record-high for the contract development and manufacturing organization (CDMO) and a 25% jump on fiscal year 2022 sales. Some of this was attributed to capital expenditure projects coming online, providing extra mammalian capacity for biologics during the year. Moreover, when Avid’s…